The incidence and management of persistent cystoid macular oedema following uncomplicated cataract surgery-a Scottish Ophthalmological Surveillance Unit study.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
21
02
2020
accepted:
16
04
2020
revised:
16
04
2020
pubmed:
8
5
2020
medline:
22
6
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Post-operative cystoid macular oedema (CMO) can cause deterioration of vision following routine cataract surgery. The incidence of persistent CMO (pCMO; defined as CMO present after 3 months) following uncomplicated surgery is uncertain. We wished to identify the incidence, management and visual outcomes of such patients. A Scottish Ophthalmological Surveillance Unit (SOSU) questionnaire was sent monthly to every ophthalmic specialist in Scotland over an 18-month period from 1st January 2018 asking them to report all new patients with pCMO confirmed on OCT scanning following uncomplicated cataract surgery. A follow-up questionnaire was sent 9 months after initial presentation. Fourteen cases of pCMO were reported, giving an incidence of 2.2 cases of pCMO per 10,000 uncomplicated cataract surgeries. Mean age was 74.9 years (SD 10.2; range 44-86) with a male preponderance (72.7%). Two patients developed pCMO in each eye. Six cases (46.2%) had hypertension and one had diabetes. Three eyes required intracameral adjuncts (two iris hooks, one intracameral phenylephrine). Postoperative visual acuity (VA) at 3 months was logMAR 0.48 (0.2-0.8). Average mean central retinal thickness (CRT) at 3 months was 497microns (270-788). The most common initial treatment comprised topical steroids and topical NSAIDs (61.5%). Other management strategies included systemic steroids, intravitreal steroids and oral acetazolamide. At 1-year post-op, mean VA was logMAR 0.18 (0.1-0.3) with average mean CRT of 327microns (245-488). We identified a low incidence of pCMO following uncomplicated cataract surgery in Scotland (0.02%), with inconsistent and variable management regimes. A nationally agreed treatment protocol is required.
Identifiants
pubmed: 32376978
doi: 10.1038/s41433-020-0908-y
pii: 10.1038/s41433-020-0908-y
pmc: PMC7202460
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-591Références
Royal College of Ophthalmologists (UK). National ophthalmology database audit. 2019. https://nodaudit.org.uk/u/docs/20/urxqilwxmv/NOD%20Audit%20Annual%20Report%202019.pdf , Accessed 4 Feb 2020.
Busbee BG, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology. 2002;109:606–12.
doi: 10.1016/S0161-6420(01)00971-X
Law SK, Kim E, Yu F, Caprioli J. Clinical cystoid macular edema after cataract surgery in glaucoma patients. J Glaucoma. 2010;19:100–4.
pubmed: 20160577
Chu CJ, Johnston RL, Buscombe C, Sallam AB, Mohamed Q, Yang YC. Risk factors and incidence of macular edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123:316–23.
doi: 10.1016/j.ophtha.2015.10.001
Kim SJ, Schoenberger SD, Thorne JE, Ehlers JP, Yeh S, Bakri SJ. Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2015;122:2159–68.
doi: 10.1016/j.ophtha.2015.05.014
Bellocq D, Pierre-Kahn V, Matonti F, Burillon C, Voirin N, Dot C, et al. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. Br J Ophthalmol. 2017;101:333–41.
pubmed: 27190126
McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, et al. Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC Ophthalmol. 2017;17:16.
doi: 10.1186/s12886-017-0405-7
Wendel C, Zakrzewski H, Carleton B, Etminan M, Mikelberg FS. Association of postoperative topical prostaglandin analog or beta-blocker use and incidence of pseudophakic cystoid macular edema. J Glaucoma. 2018;27:402–6.
doi: 10.1097/IJG.0000000000000929
Wielders LHP, Schouten J, Winkens B, van den Biggelaar F, Veldhuizen CA, Findl O, et al. European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1. J Cataract Refract Surg. 2018;44:429–39.
doi: 10.1016/j.jcrs.2018.01.029
Wielders LHP, Schouten J, Winkens B, van den Biggelaar F, Veldhuizen CA, Murta JCN, et al. Randomized controlled European multicenter trial on the prevention of cystoid macular edema after cataract surgery in diabetics: ESCRS PREMED Study Report 2. J Cataract Refract Surg. 2018;44:836–47.
doi: 10.1016/j.jcrs.2018.05.015
Flach AJ. The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc. 1998;96:557–634.
pubmed: 10360304
pmcid: 1298410
Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33:1550–8.
doi: 10.1016/j.jcrs.2007.05.013
Schmier JK, Halpern MT, Covert DW, Matthews GP. Evaluation of costs for cystoid macular edema among patients after cataract surgery. Retina. 2007;27:621–8.
doi: 10.1097/01.iae.0000249577.92800.c0
Karacorlu M, Ozdemir H, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand. 2003;81:648–52.
doi: 10.1046/j.1395-3907.2003.0146.x
Yonekawa Y, Kim IK. Pseudophakic cystoid macular edema. Curr Opin Ophthalmol. 2012;23:26–32.
doi: 10.1097/ICU.0b013e32834cd5f8
Grzybowski A, Sikorski BL, Ascaso FJ, Huerva V. Pseudophakic cystoid macular edema: update 2016. Clin Inter Aging. 2016;11:1221–9.
doi: 10.2147/CIA.S111761
Puliafito CA, Hee MR, Lin CP, Reichel E, Schuman JS, Duker JS, et al. Imaging of macular diseases with optical coherence tomography. Ophthalmology. 1995;102:217–29.
doi: 10.1016/S0161-6420(95)31032-9
Guo S, Patel S, Baumrind B, Johnson K, Levinsohn D, Marcus E, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60:123–37.
doi: 10.1016/j.survophthal.2014.08.005
Foot B, Stanford M, Rahi J, Thompson J. The British Ophthalmological Surveillance Unit: an evaluation of the first 3 years. Eye (Lond). 2003;17:9–15.
doi: 10.1038/sj.eye.6700233
Surgical Procedures. Information Services Division. NHS National Services Scotland. 2019. Accessed April 2020 at https://www.isdscotland.org/products-and-services/scottish-atlas-of-variation/view-the-atlas/surgical-procedures.asp .
Rath EZ, Frank RN, Shin DH, Kim C. Risk factors for retinal vein occlusions. A case-control study. Ophthalmology. 1992;99:509–14.
doi: 10.1016/S0161-6420(92)31940-2
Ponto KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS, et al. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost. 2015;13:1254–63.
doi: 10.1111/jth.12982
Martinez F, Furio E, Fabia MJ, Perez AV, Gonzalez-Albert V, Rojo-Martinez G, et al. Risk factors associated with retinal vein occlusion. Int J Clin Pr. 2014;68:871–81.
doi: 10.1111/ijcp.12390
Kida T, Morishita S, Kakurai K, Suzuki H, Oku H, Ikeda T. Treatment of systemic hypertension is important for improvement of macular edema associated with retinal vein occlusion. Clin Ophthalmol. 2014;8:955–8.
doi: 10.2147/OPTH.S63368
Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186–92.
doi: 10.1001/archopht.123.2.186
Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987;103:479–86.
doi: 10.1016/S0002-9394(14)74268-0
Loewenstein A, Zur D. Postsurgical cystoid macular edema. Dev Ophthalmol. 2010;47:148–59.
doi: 10.1159/000320078
Lobo C. Pseudophakic cystoid macular edema. Ophthalmologica. 2012;227:61–7.
doi: 10.1159/000331277
Han JV, Patel DV, Squirrell D, McGhee CN. Cystoid macular oedema following cataract surgery: A review. Clin Exp Ophthalmol. 2019;47:346–56.
doi: 10.1111/ceo.13513
Packer M, Lowe J, Fine H. Incidence of acute postoperative cystoid macular edema in clinical practice. J Cataract Refract Surg. 2012;38:2108–11.
doi: 10.1016/j.jcrs.2012.07.029
Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub-Tenon’s corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology. 1997;104:2003–8.
doi: 10.1016/S0161-6420(97)30065-7
Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol. 2005;89:1420–2.
doi: 10.1136/bjo.2005.073817
Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, et al. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology. 2009;116:1481–7, 7.e1.
doi: 10.1016/j.ophtha.2009.04.006
Kessel L, Tendal B, Jorgensen KJ, Erngaard D, Flesner P, Andresen JL, et al. Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014;121:1915–24.
doi: 10.1016/j.ophtha.2014.04.035
Mayer WJ, Kurz S, Wolf A, Kook D, Kreutzer T, Kampik A, et al. Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome. J Cataract Refract Surg. 2015;41:1954–61.
doi: 10.1016/j.jcrs.2015.10.025
Juthani VV, Clearfield E, Chuck RS. Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery. Cochrane Database Syst Rev. 2017;7:Cd010516.
pubmed: 28670710
Yuksel B, Uzunel UD, Kerci SG, Sagban L, Kusbeci T, Orsel T. Comparison of subtenon triamcinolone acetonide injection with topical nepafenac for the treatment of pseudophakic cystoid macular edema. Ocul Immunol Inflamm. 2017;25:513–9.
doi: 10.3109/09273948.2016.1147587
Jacobson DR, Dellaporta A. Natural history of cystoid macular edema after cataract extraction. Am J Ophthalmol. 1974;77:445–7.
doi: 10.1016/0002-9394(74)90451-6
Suleman H, Mathew M, Lakshmanan A, Abedin A, Orr G. Orbital floor triamcinolone acetonide in the treatment of pseudophakic cystoid macular oedema. Acta Ophthalmol. 2008;86. https://doi.org/10.1111/j.1755-3768.2008.6417.x .
Curkovic T, Vukojevic N, Bucan K. Treatment of pseudophakic cystoid macular oedema. Coll Antropol. 2005;29:103–5.
pubmed: 16193688
Hunter AA, Modjtahedi SP, Long K, Zawadzki R, Chin EK, Caspar JJ, et al. Improving visual outcomes by preserving outer retina morphology in eyes with resolved pseudophakic cystoid macular edema. J Cataract Refract Surg. 2014;40:626–31.
doi: 10.1016/j.jcrs.2013.09.018
Lundström M, Behndig A, Kugelberg M, Montan P, Stenevi U, Thorburn W. Decreasing rate of capsule complications in cataract surgery: eight-year study of incidence, risk factors, and data validity by the Swedish National Cataract Register. J Cataract Refract Surg. 2011;37:1762–7.
doi: 10.1016/j.jcrs.2011.05.022